Haemonetics (HAE) Stock Forecast, Price Target & Predictions
HAE Stock Forecast
Haemonetics stock forecast is as follows: an average price target of $104.33 (represents a 37.11% upside from HAE’s last price of $76.09) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
HAE Price Target
The average price target for Haemonetics (HAE) is $104.33 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $116.00 to $85.00. This represents a potential 37.11% upside from HAE's last price of $76.09.
HAE Analyst Ratings
According to 6 Wall Street analysts, Haemonetics's rating consensus is 'Buy'. The analyst rating breakdown for HAE stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haemonetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Kristen Stewart | C.L. King | $116.00 | $73.26 | 58.34% | 52.45% |
| Sep 11, 2024 | Craig Bijou | Bank of America Securities | $85.00 | $71.61 | 18.69% | 11.71% |
| Jun 12, 2024 | Mike Matson | Needham | $112.00 | $83.41 | 34.28% | 47.19% |
The latest Haemonetics stock forecast, released on Sep 13, 2024 by Kristen Stewart from C.L. King, set a price target of $116.00, which represents a 58.34% increase from the stock price at the time of the forecast ($73.26), and a 52.45% increase from HAE last price ($76.09).
Haemonetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 3 |
| Avg Price Target | $100.50 | $100.50 | $104.33 |
| Last Closing Price | $76.09 | $76.09 | $76.09 |
| Upside/Downside | 32.08% | 32.08% | 37.11% |
In the current month, the average price target of Haemonetics stock is $100.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 32.08% increase as opposed to Haemonetics's last price of $76.09. This month's average price target is down 0.00% compared to last quarter, and down -3.67% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Bank of America Securities | - | Neutral | Initialise |
| Sep 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 10, 2024 | Citigroup | Underperform | Underperform | Hold |
| Sep 10, 2024 | BTIG | - | Buy | Initialise |
| Aug 22, 2024 | Needham | Market Outperform | Market Outperform | Hold |
| Jun 12, 2024 | Needham | Hold | Buy | Upgrade |
| May 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 12, 2023 | William Blair | Outperform | Outperform | Hold |
| Jul 01, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Haemonetics's last stock rating was published by Bank of America Securities on Sep 11, 2024. The company Initialise its HAE rating from "null" to "Neutral".
Haemonetics Financial Forecast
Haemonetics Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $336.25M | $318.18M | $311.33M | $304.42M | $305.30M | $297.49M | $261.46M | $265.00M | - | $239.90M | $228.53M | $225.03M | $240.37M | $209.49M | $195.58M | $238.49M | $258.97M |
| Avg Forecast | $404.88M | $394.17M | $374.08M | $365.15M | $378.80M | $371.59M | $355.50M | $348.80M | $360.47M | $357.59M | $342.61M | $335.08M | $329.53M | $320.84M | $313.15M | $292.74M | $290.79M | $299.56M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| High Forecast | $411.05M | $400.17M | $379.78M | $370.72M | $384.57M | $377.26M | $360.92M | $354.11M | $365.96M | $363.04M | $347.27M | $340.19M | $334.55M | $325.06M | $319.83M | $297.20M | $295.22M | $304.12M | $273.32M | $249.00M | $262.57M | $271.03M | $245.95M | $224.09M | $227.72M | $229.02M | $212.06M | $202.48M | $251.77M | $260.82M |
| Low Forecast | $400.61M | $390.02M | $370.14M | $361.31M | $374.80M | $367.68M | $351.75M | $345.12M | $356.67M | $353.82M | $339.95M | $331.55M | $326.05M | $318.18M | $309.03M | $289.66M | $287.72M | $296.40M | $266.38M | $249.00M | $253.27M | $261.43M | $237.24M | $216.16M | $219.65M | $220.91M | $204.55M | $195.31M | $242.85M | $251.59M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.02% | 1.06% | 1.05% | 1.02% | 1.10% | 1.05% | 1.03% | - | 1.00% | 1.04% | 1.01% | 1.07% | 1.01% | 0.99% | 0.97% | 1.01% |
Haemonetics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $329.53M, with a low forecast of $326.05M, and a high forecast of $334.55M. HAE's average Quarter revenue forecast represents a -2.00% decrease compared to the company's last Quarter revenue of $336.25M (Dec 23).
Haemonetics EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $69.51M | $35.30M | $53.66M | $59.11M | $66.85M | $69.79M | $53.21M | $31.26M | - | $48.04M | $7.22M | $536.00K | $39.31M | $48.16M | $33.47M | $54.77M | $69.84M |
| Avg Forecast | $84.86M | $82.62M | $78.41M | $76.54M | $79.39M | $77.89M | $74.51M | $73.11M | $75.55M | $74.95M | $71.81M | $70.23M | $48.82M | $67.25M | $65.64M | $61.36M | $44.38M | $62.79M | $55.36M | $52.19M | $40.34M | $67.61M | $50.33M | $20.62M | $965.37K | $46.13M | $62.48M | $28.48M | $57.77M | $51.87M |
| High Forecast | $86.16M | $83.88M | $79.60M | $77.70M | $80.60M | $79.07M | $75.65M | $74.22M | $76.70M | $76.09M | $72.79M | $71.30M | $58.58M | $68.13M | $67.04M | $62.29M | $53.25M | $63.74M | $66.44M | $52.19M | $48.41M | $81.14M | $60.40M | $24.74M | $1.16M | $55.36M | $74.98M | $34.18M | $69.33M | $62.24M |
| Low Forecast | $83.97M | $81.75M | $77.58M | $75.73M | $78.56M | $77.06M | $73.73M | $72.34M | $74.76M | $74.16M | $71.25M | $69.49M | $39.05M | $66.69M | $64.77M | $60.71M | $35.50M | $62.13M | $44.29M | $52.19M | $32.28M | $54.09M | $40.27M | $16.50M | $772.30K | $36.91M | $49.98M | $22.79M | $46.22M | $41.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.54% | 0.87% | 1.33% | 1.06% | 1.26% | 1.02% | 0.77% | - | 0.95% | 0.35% | 0.56% | 0.85% | 0.77% | 1.17% | 0.95% | 1.35% |
1 analysts predict HAE's average Quarter EBITDA for Mar 24 to be $48.82M, with a high of $58.58M and a low of $39.05M. This is -29.77% lower than Haemonetics's previous annual EBITDA (Dec 23) of $69.51M.
Haemonetics Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $31.24M | $24.91M | $41.04M | $29.38M | $32.94M | $33.20M | $19.88M | $9.74M | - | $14.86M | $-4.45M | $-11.04M | $31.88M | $48.10M | $10.53M | $17.62M | $29.89M |
| Avg Forecast | $88.61M | $84.77M | $74.14M | $69.70M | $75.55M | $71.70M | $66.53M | $61.58M | $66.10M | $63.22M | $55.43M | $51.85M | $10.80M | $48.55M | $45.78M | $37.28M | $9.82M | $42.12M | $17.12M | $26.22M | $8.93M | $7.04K | $15.56M | $-4.17M | $-14.50M | $24.03M | $37.73M | $9.24M | $18.59M | $22.81M |
| High Forecast | $90.36M | $86.45M | $75.61M | $71.08M | $77.04M | $73.12M | $67.85M | $62.80M | $67.40M | $64.47M | $56.52M | $52.87M | $12.97M | $50.05M | $49.89M | $38.02M | $11.79M | $42.95M | $20.54M | $26.22M | $10.72M | $8.45K | $18.68M | $-3.34M | $-11.60M | $28.84M | $45.27M | $11.09M | $22.31M | $27.38M |
| Low Forecast | $87.39M | $83.61M | $73.13M | $68.74M | $74.51M | $70.72M | $65.62M | $60.74M | $65.19M | $62.35M | $54.42M | $51.14M | $8.64M | $47.55M | $42.69M | $36.77M | $7.86M | $41.54M | $13.70M | $26.22M | $7.14M | $5.63K | $12.45M | $-5.00M | $-17.40M | $19.23M | $30.18M | $7.39M | $14.87M | $18.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.54% | 1.10% | 2.99% | 0.78% | 1.94% | 0.76% | 1.09% | - | 0.95% | 1.07% | 0.76% | 1.33% | 1.28% | 1.14% | 0.95% | 1.31% |
Haemonetics's average Quarter net income forecast for Mar 24 is $10.80M, with a range of $8.64M to $12.97M. HAE's average Quarter net income forecast represents a -65.42% decrease compared to the company's last Quarter net income of $31.24M (Dec 23).
Haemonetics SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $111.71M | $104.90M | $93.48M | $97.38M | $94.66M | $92.41M | $92.23M | $91.84M | - | $75.78M | $91.22M | $83.71M | $73.45M | $71.70M | $69.54M | $78.57M | $78.27M |
| Avg Forecast | $129.58M | $126.16M | $119.73M | $116.87M | $121.24M | $118.93M | $113.78M | $111.63M | $115.37M | $114.45M | $109.65M | $107.25M | $101.87M | $102.69M | $100.23M | $93.69M | $92.61M | $95.88M | $87.33M | $79.69M | $84.19M | $71.04M | $79.39M | $85.40M | $78.16M | $55.37M | $56.23M | $61.06M | $82.88M | $59.73M |
| High Forecast | $131.56M | $128.08M | $121.55M | $118.65M | $123.08M | $120.74M | $115.51M | $113.34M | $117.13M | $116.19M | $111.15M | $108.88M | $122.24M | $104.04M | $102.36M | $95.12M | $111.13M | $97.34M | $104.79M | $79.69M | $101.03M | $85.25M | $95.26M | $102.47M | $93.79M | $66.44M | $67.48M | $73.27M | $99.46M | $71.68M |
| Low Forecast | $128.22M | $124.83M | $118.47M | $115.64M | $119.96M | $117.68M | $112.58M | $110.46M | $114.15M | $113.24M | $108.80M | $106.12M | $81.49M | $101.84M | $98.91M | $92.71M | $74.09M | $94.87M | $69.86M | $79.69M | $67.35M | $56.83M | $63.51M | $68.32M | $62.53M | $44.29M | $44.99M | $48.85M | $66.30M | $47.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.05% | 1.00% | 1.05% | 0.99% | 1.06% | 1.16% | 1.09% | - | 0.95% | 1.07% | 1.07% | 1.33% | 1.28% | 1.14% | 0.95% | 1.31% |
Haemonetics's average Quarter SG&A projection for Mar 24 is $101.87M, based on 1 Wall Street analysts, with a range of $81.49M to $122.24M. The forecast indicates a -8.81% fall compared to HAE last annual SG&A of $111.71M (Dec 23).
Haemonetics EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 3 | 1 | 3 | 6 | 3 | 3 | 3 | 3 | 4 | 1 | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.62 | $0.49 | $0.81 | $0.58 | $0.65 | $0.65 | $0.39 | $0.19 | - | $0.29 | $-0.09 | $-0.22 | $0.63 | $0.95 | $0.21 | $0.34 | $0.59 |
| Avg Forecast | $1.72 | $1.64 | $1.44 | $1.35 | $1.47 | $1.39 | $1.29 | $1.19 | $1.28 | $1.23 | $1.07 | $1.01 | $0.89 | $0.94 | $0.89 | $0.72 | $0.70 | $0.82 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| High Forecast | $1.75 | $1.68 | $1.47 | $1.38 | $1.49 | $1.42 | $1.32 | $1.22 | $1.31 | $1.25 | $1.10 | $1.03 | $0.91 | $0.97 | $0.97 | $0.74 | $0.72 | $0.83 | $0.69 | $0.51 | $0.62 | $0.75 | $0.62 | $0.46 | $0.69 | $0.67 | $0.52 | $0.43 | $0.75 | $0.78 |
| Low Forecast | $1.69 | $1.62 | $1.42 | $1.33 | $1.45 | $1.37 | $1.27 | $1.18 | $1.26 | $1.21 | $1.06 | $0.99 | $0.88 | $0.92 | $0.83 | $0.71 | $0.69 | $0.81 | $0.66 | $0.51 | $0.59 | $0.72 | $0.59 | $0.44 | $0.66 | $0.64 | $0.50 | $0.41 | $0.71 | $0.74 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.55% | 1.12% | 0.82% | 0.80% | 0.96% | 0.76% | 0.32% | - | 0.48% | -0.19% | -0.33% | 0.96% | 1.88% | 0.51% | 0.47% | 0.78% |
According to 1 Wall Street analysts, Haemonetics's projected average Quarter EPS for Mar 24 is $0.89, with a low estimate of $0.88 and a high estimate of $0.91. This represents a 43.84% increase compared to HAE previous annual EPS of $0.62 (Dec 23).
Haemonetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| AKYA | Akoya Biosciences | $2.94 | $7.90 | 168.71% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| ATRC | AtriCure | $28.21 | $49.57 | 75.72% | Buy |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| TFX | Teleflex | $246.05 | $304.09 | 23.59% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| WST | West Pharmaceutical Services | $300.67 | $345.33 | 14.85% | Buy |
| HOLX | Hologic | $81.15 | $78.92 | -2.75% | Buy |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| ALC | Alcon | $98.50 | $93.34 | -5.24% | Buy |
| RMD | ResMed | $248.93 | $209.33 | -15.91% | Hold |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| ATR | AptarGroup | $152.28 | $100.00 | -34.33% | Buy |
HAE Forecast FAQ
Is Haemonetics a good buy?
Yes, according to 6 Wall Street analysts, Haemonetics (HAE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of HAE's total ratings.
What is HAE's price target?
Haemonetics (HAE) average price target is $104.33 with a range of $85 to $116, implying a 37.11% from its last price of $76.09. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Haemonetics stock go up soon?
According to Wall Street analysts' prediction for HAE stock, the company can go up by 37.11% (from the last price of $76.09 to the average price target of $104.33), up by 52.45% based on the highest stock price target, and up by 11.71% based on the lowest stock price target.
Can Haemonetics stock reach $110?
HAE's highest twelve months analyst stock price target of $116 supports the claim that Haemonetics can reach $110 in the near future.
What is Haemonetics's current price target trend?
2 Wall Street analysts forecast a $100.5 price target for Haemonetics (HAE) this month, up 32.08% from its last price of $76.09. Compared to the last 3 and 12 months, the average price target increased by 32.08% and increased by 37.11%, respectively.
What are Haemonetics's analysts' financial forecasts?
Haemonetics's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $1.45B (high $1.48B, low $1.44B), average EBITDA is $304.9M (high $309.54M, low $301.69M), average net income is $275.36M (high $280.82M, low $271.59M), average SG&A $465.58M (high $472.68M, low $460.68M), and average EPS is $5.34 (high $5.45, low $5.27). HAE's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $1.54B (high $1.56B, low $1.52B), average EBITDA is $322.42M (high $327.33M, low $319.02M), average net income is $317.22M (high $323.5M, low $312.87M), average SG&A $492.34M (high $499.84M, low $487.15M), and average EPS is $6.15 (high $6.27, low $6.07).
Did the HAE's actual financial results beat the analysts' financial forecasts?
Based on Haemonetics's last annual report (Mar 2023), the company's revenue was $1.17B, beating the average analysts forecast of $1.11B by 5.42%. Apple's EBITDA was $249.34M, beating the average prediction of $214.72M by 16.12%. The company's net income was $115.4M, beating the average estimation of $95.27M by 21.13%. Apple's SG&A was $376.68M, beating the average forecast of $355.5M by 5.96%. Lastly, the company's EPS was $2.27, missing the average prediction of $2.7 by -16.08%. In terms of the last quarterly report (Dec 2023), Haemonetics's revenue was $336.25M, beating the average analysts' forecast of $320.84M by 4.80%. The company's EBITDA was $69.51M, beating the average prediction of $67.25M by 3.36%. Haemonetics's net income was $31.24M, missing the average estimation of $48.55M by -35.65%. The company's SG&A was $111.71M, beating the average forecast of $102.69M by 8.79%. Lastly, the company's EPS was $0.62, missing the average prediction of $0.941 by -34.15%